Overview of the immune biology of allogeneic hematopoietic stem cell transplantation - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 16

[72] Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expres-
sion of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory
and activated T cells. J Exp Med 2006;203(7):1693-700.
[73] Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and
call me in the morning. Immunity 2009;30(5):656-65.
[74] Annunziato F, Romagnani S. Do studies in humans better depict Th17 cells? Blood
2009;114(11):2213-19.
[75] Rowell E, Wilson CB. Programming perpetual T helper cell plasticity. Immunity
2009;30(1):7-9.
[76] Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, et al. Infusion
of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood:
safety profile and detection kinetics. Blood 2010;117(3):1061-70.
[77] Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent
GVHD and promote immune reconstitution in HLA-haploidentical transplantation.
Blood 2010;117(14):3921-8.
[78] Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, et al. Massive
ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of
in vivo functional activity. Sci Transl Med 2011;3(83); 83ra41.
[79] Zeng D, Lewis D, Dejbakhsh-Jones S, Lan F, Garcia-Ojeda M, Sibley R, et al. Bone mar-
row NK1.1(-) and NK1.1( + ) T cells reciprocally regulate acute graft versus host disease. J
Exp Med 1999;189(7):1073-81.
[80] Kohrt HE, Turnbull BB, Heydari K, Shizuru JA, Laport GG, Miklos DB, et al. TLI and ATG
conditioning with low risk of graft-versus-host disease retains anti-tumor reactions
after allogeneic hematopoietic cell transplantation from related and unrelated donors.
Blood 2009;114(5):1099-1109.
[81] Lowsky R, Takahashi T, Liu YP, Dejbakhsh-Jones S, Grumet FC, Shizuru JA, et al. Protec-
tive conditioning for acute graft-versus-host disease. N Engl J Med 2005;353(13):1321-31.
[82] Morris ES, MacDonald KP, Kuns RD, Morris HM, Banovic T, Don AL, et al. Induction of
natural killer T cell-dependent alloreactivity by administration of granulocyte colony-
stimulating factor after bone marrow transplantation. Nat Med 2009;15(4):436-41.
[83] Dong C. TH17 cells in development: an updated view of their molecular identity and
genetic programming. Nat Rev Immunol 2008;8(5):337-48.
[84] Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS. In vitro -
differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe
cutaneous and pulmonary pathologic manifestations. Blood 2009;113(6):1365-74.
[85] Kappel LW, Goldberg GL, King CG, Suh DY, Smith OM, Ligh C, et al. IL-17 contributes
to CD4-mediated graft-versus-host disease. Blood 2009;113(4):945-52.
[86] Yi T, Zhao D, Lin CL, Zhang C, Chen Y, Todorov I, et al. Absence of donor Th17 leads to
augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood
2008;112(5):2101-10.
[87] Ratajczak P, Janin A, Peffault de Latour R, Leboeuf C, Desveaux A, Keyvanfar K, et al.
Th17/Treg ratio in human graft-versus-host disease. Blood 2011;116(7):1165-71.
[88] Panoskaltsis-Mortari A, Price A, Hermanson JR, Taras E, Lees C, Serody JS, et al. In vivo
imaging of graft-versus-host-disease in mice. Blood 2004;103(9):3590-8.
[89] Chakraverty R, Cote D, Buchli J, Cotter P, Hsu R, Zhao G, et al. An inflammatory check-
point regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J
Exp Med 2006;203(8):2021-31.
[90] Lin MT, Storer B, Martin PJ, Tseng LH, Gooley T, Chen PJ, et al. Relation of an inter-
leukin-10 promoter polymorphism to graft-versus-host disease and survival after
hematopoietic-cell transplantation. N Engl J Med 2003;349(23):2201-10.
[91] Baker MB, Altman NH, Podack ER, Levy RB. The role of cell-mediated cytotoxicity in
acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J
Exp Med 1996;183(6):2645-56.
[92] Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in
both functional fas ligand and perforin show residual cytolytic activity yet lose their
capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996;183(2):657-61.
[93] Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM. Recipient tumor
necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early
mortality and acute graft-versus-host disease severity in HLA-matched sibling bone
marrow transplants. Blood 1999;94(11):3941-6.
[94] Choi SW, Kitko CL, Braun T, Paczesny S, Yanik G, Mineishi S, et al. Change in plasma
tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic
transplantation correlates with severity and incidence of GVHD and survival. Blood
2008;112(4):1539-42.

16